Virtual Library

Start Your Search

Amanda Rosberg



Author of

  • +

    EP1.04 - Immuno-oncology (ID 194)

    • Event: WCLC 2019
    • Type: E-Poster Viewing in the Exhibit Hall
    • Track: Immuno-oncology
    • Presentations: 1
    • Now Available
    • Moderators:
    • Coordinates: 9/08/2019, 08:00 - 18:00, Exhibit Hall
    • +

      EP1.04-35 - Immunotherapy in Non-Small Cell Lung Cancer (NSCLC) – Experiences from Clinical Practice – Sweden (Now Available) (ID 1002)

      08:00 - 18:00  |  Author(s): Amanda Rosberg

      • Abstract
      • Slides

      Background

      Lung cancer is the leading cause of cancer-related mortality worldwide, with NSCLC accounting for over 85% of all cases. Until recently, chemotherapy – characterized by some benefit but only rare durable responses – was the only treatment option for patients (pts) with NSCLC whose tumors lacked targetable mutations. By contrast, immune checkpoint inhibitors have demonstrated durable responses and represent the opportunity of a new treatment approach for pts with NSCLC.

      Method

      A chart review was conducted of incident cases of all pts who had been treated with immune check point inhibitor during the last 3 years in 4 hospitals. Data was retrospectively collected: pts characteristics, tumour characteristics, treatment details, tumor stage, adverse events, survival.

      Result

      In total, 244 pts, 114 (46.8%) males were given immunotherapy. Mean and median age was 70.11, 72.3 yrs. 219 (89.6%) were smoker or former smoker. 168 (68.9%) with PS 0-1, 61 (24.9%) PS 2. Most of the pts had stage IVA 119(48.6%), IIIB 34 (13.9%), IIIA 31 (12.7%). Adenocarcinoma in 151 (61.6%) and squamous cell carcinoma in 70(29.6%) of the pts. PDL1 < 1% in 30(12.2%), 1-49% in 66(27.3%) and >50% in 92 (37.6%). Pembrolizumab was given either as 1st or 2nd line in 120 (49.0%) ,nivolumab as 2nd, 3rd or 4th line in 85 (34.7%) and atezolizumab 31 (12.7%) as 2nd or 3rd line. 76(31.1%) had partial response,3 (1.2%) complete response, 41 (16.8%) stable disease, 64 (26.2%) progressive disease. 60 (24.5%) still on treatment. Most adverse events (AE) was pneumonitis 13 (5.2%), colitis 10 (4.1%), Thyroiditis 8 (3.2%).

      Conclusion

      Pembrolizumab has been given mostly in first line treatment due to high PD-L1 but nivolumab or tecentriq most in 2nd or 3rd line. Overall responses was 49.1%. Very few AE mostly pneumonitis and colitis

      More data will be presented during the conference

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.